BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Mersana shows that B7-H4 expression matters
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
Jemperli aims for ovarian white space
But, like Merck two weeks ago, GSK has failed to hit overall survival.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
